Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain

Slides:

Advertisements

Similar presentations

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

Advertisements

One-Year rTMS Treatment for Refractory Trigeminal Neuralgia

A Randomized, Open, Parallel Group, Multicenter Trial to Investigate Analgesic Efficacy and Safety of a New Transdermal Fentanyl Patch Compared to Standard.

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Postoperative pain and early quality of life after radiofrequency ablation and mechanochemical endovenous ablation of incompetent great saphenous veins

Clinical Trial Results with OROS® Hydromorphone

Geoffrey K. Mitchell, PhD, FRACGP, FAChPM, Janet R

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Use of strong opioids in advanced cancer pain: a randomized trial

Postoperative pain and early quality of life after radiofrequency ablation and mechanochemical endovenous ablation of incompetent great saphenous veins

An Assessment of the Safety, Eff icacy, and Acceptability of Intranasal Fentanyl Citrate in the Management of Cancer-Related Breakthrough Pain Giovambattista.

A Randomized, Open, Parallel Group, Multicenter Trial to Investigate Analgesic Efficacy and Safety of a New Transdermal Fentanyl Patch Compared to Standard.

The Impact of Chronic Pain on Life in the Household

Analgesic and Sedative Effects of Melatonin in Temporomandibular Disorders: A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study Liliane.

Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to- Severe Osteoarthritis Pain Jacques R. Caldwell, MD, Ronald J. Rapoport,

Pain Severity in Diabetic Peripheral Neuropathy is Associated with Patient Functioning, Symptom Levels of Anxiety and Depression, and Sleep Mugdha Gore,

A Double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension Using an Oral Mucosal Cannabinoid Extract for Treatment of Chemotherapy-Induced.

David M. Simpson, MD, Lydia Estanislao, MD, Stephen J

The Impact of Pain Management on Quality of Life

Midazolam as Adjunct Therapy to Morphine in the Alleviation of Severe Dyspnea Perception in Patients with Advanced Cancer Alfredo H. Navigante, MD, PhD,

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

NMDA-Receptor Antagonists in Neuropathic Pain

Symptomatic Therapy of Dyspnea with Strong Opioids and Its Effect on Ventilation in Palliative Care Patients Katri Elina Clemens, MD, PhD, Eberhard Klaschik,

Eduardo Bruera, MD, Raul Sala, MD, Odette Spruyt, MD, J

The Effect of a Multimodal Intervention on Treatment-Related Symptoms in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Controlled.

Double-Blind, Placebo-Controlled Trial of Lamotrigine in Combination with Other Medications for Neuropathic Pain Marianne Silver, MS, David Blum, MD,

David M. Dosa, MD, MPH, David D

Jean-Pierre Van Buyten, MD Journal of Pain and Symptom Management

Fentanyl-Induced Neurotoxicity and Paradoxic Pain

Samuel J Hassenbusch, MD, PhD, Russell K Portenoy, MD

One-Year rTMS Treatment for Refractory Trigeminal Neuralgia

Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic.

Transdermal Fentanyl for Chronic Pain in AIDS

Redefining Appropriate Treatment Expectations

Long-Term Analgesic Effects of Transcranial Direct Current Stimulation of the Motor Cortex on Phantom Limb and Stump Pain: A Case Report Nadia Bolognini,

Treatment of Cancer Pain with Noninvasive Brain Stimulation

Changes in Symptom Intensity Among Cancer Patients Receiving Outpatient Palliative Care Jung Hun Kang, MD, PhD, Jung Hye Kwon, MD, PhD, David Hui, MD,

Characterization of the early pharmacodynamic profile of oral methadone for cancer- related breakthrough pain: a pilot study Kim Fisher, PhD, Carla Stiles,

Paul A. Sloan, MD, Dwight E. Moulin, MD, FRCP(C), Helen Hays, MD

Amitriptyline in the Treatment of Chemotherapy-Induced Neuropathic Symptoms Anna-Liisa Kautio, MD, Maija Haanpää, MD, PhD, Tiina Saarto, MD, PhD, Eija.

Barrie R. Cassileth, PhD, Andrew J. Vickers, PhD

The effect of transdermal fentanyl treatment on serum cortisol concentrations in patients with non-cancer pain Emine Ozyuvaci, MD, Nergis Yanmaz Alnigenis,

A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee

Strategies in Pain Management

Cancer Pain Assessment and Management Recommendations by Hospice Nurses Paul A Sloan, MD, Barbara L Vanderveer, BSN, Janet S Snapp, BSN, Mitzi Johnson,

Requests to Forgo Potentially Life-Prolonging Treatment and to Hasten Death in Terminally Ill Cancer Patients: A Prospective Study Jean-Jacques Georges,

Methadone Analgesia in Cancer Pain Patients on Chronic Methadone Maintenance Therapy Paolo L Manfredi, MD, Gilbert R Gonzales, Andrea L Cheville, Craig.

The COX-2 Specific Inhibitor, Valdecoxib, Is An Effective, Opioid-Sparing Analgesic in Patients Undergoing Total Knee Arthroplasty Lowell W Reynolds,

Atropine, Hyoscine Butylbromide, or Scopolamine Are Equally Effective for the Treatment of Death Rattle in Terminal Care Hans Wildiers, MD, PhD, Chris.

Cancer Pain Education Journal of Pain and Symptom Management

Transdermal Fentanyl in Opioid-Naive Cancer Pain Patients

Richard J Gralla, MD, Frank Griesinger, MD, PhD

A Randomized, Open, Parallel Group, Multicenter Trial to Investigate Analgesic Efficacy and Safety of a New Transdermal Fentanyl Patch Compared to Standard.

No evidence for sex differences in the severity and treatment of cancer pain Janet M. Edrington, RN, MS, Steven Paul, PhD, Marylin Dodd, RN, PhD, Claudia.

Andy Kusuma, MD, Anurag Relan, MD, André C

Primer of statistics in dental research: Part I

Gabapentin and an Opioid Combination Versus Opioid Alone for the Management of Neuropathic Cancer Pain: A Randomized Open Trial Kader Keskinbora, MD,

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

James T. Lin, MD, Paul Mathew, MD

Efficacy and Safety of Transdermal Buprenorphine: A Randomized, Placebo-Controlled Trial in 289 Patients with Severe Cancer Pain Philippe Poulain, MD,

Physical Function in Patients with Cancer

Nathaniel P Katz, MD Journal of Pain and Symptom Management

Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial Zbigniew Zylicz, MD, PhD, Malgorzata Krajnik, MD, Adriaan.

Effects of Prophylactic Subcutaneous Fentanyl on Exercise-Induced Breakthrough Dyspnea in Cancer Patients: A Preliminary Double-Blind, Randomized, Controlled.

Using the Symptom Monitor in a Randomized Controlled Trial: The Effect on Symptom Prevalence and Severity Johanna Hoekstra, MA, Rien de Vos, PhD, Nico.

Detecting the Emergence of Chronic Pain in Sickle Cell Disease

Scrambler Therapy May Relieve Chronic Neuropathic Pain More Effectively Than Guideline-Based Drug Management: Results of a Pilot, Randomized, Controlled.

Economic Evaluation of the Fentanyl Transdermal System for the Treatment of Chronic Moderate to Severe Pain Deirdre M Neighbors, BA, Timothy J Bell,

Use of Pregabalin in the Management of Chronic Uremic Pruritus

Nausea and Vomiting Remain a Significant Clinical Problem

Presentation transcript:

Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain Paul L.I. Dellemijn, MD, PhD, Hans van Duijn, MD, PhD, Jan A.L. Vanneste, MD, PhD Journal of Pain and Symptom Management Volume 16, Issue 4, Pages 220-229 (October 1998) DOI: 10.1016/S0885-3924(98)00070-0

Fig. 1 Trial profile. FENtd, transdermal fentanyl Journal of Pain and Symptom Management 1998 16, 220-229DOI: (10.1016/S0885-3924(98)00070-0)

Fig. 2 Average versus maximal pain relief with FENtd. Symbols: black circles: pain intensity; open circles: pain unpleasantness (N = 44, r(PI) = 0.96, r(PU) = 0.94, P < 0.0001, both) Journal of Pain and Symptom Management 1998 16, 220-229DOI: (10.1016/S0885-3924(98)00070-0)

Fig. 3 Average pain relief with FENiv test versus FENtd. Symbols: see Figure 2 (N = 44, r(PI) = 0.59, P < 0.0001) Journal of Pain and Symptom Management 1998 16, 220-229DOI: (10.1016/S0885-3924(98)00070-0)

Fig. 4 Time-related pain relief with FENtd. Change in % pain-intensity (PI, black symbols) and pain-unpleasantness (PU, open symbols) compared to baseline pain in the 30 patients with neuropathic pain. Error bars: 95% confidence intervals; Negative scores indicate that pain increased. OF: opioid-free observation week Journal of Pain and Symptom Management 1998 16, 220-229DOI: (10.1016/S0885-3924(98)00070-0)

Fig. 5 Type and incidence of side effects occurring at any time of transdermal fentanyl therapy in all evaluable patients (N = 44) Journal of Pain and Symptom Management 1998 16, 220-229DOI: (10.1016/S0885-3924(98)00070-0)

Fig. 6 Time-related severity of side effects (a) and sedation (b). Change in severity of side effects (a) and sedation (b) on a visual analogue scale (0–100 mm) during FENtd and the opioid-free (OF) observation week in the 30 patients who completed the trial (12 weeks). Error bars: 95% confidence intervals Journal of Pain and Symptom Management 1998 16, 220-229DOI: (10.1016/S0885-3924(98)00070-0)

Fig. 7 Changes in quality-of-life index (QLi) and depression. Comparison of the quality-of-life index and the Zung depression score between baseline (week 0), after 12 weeks of FENtd treatment (week 12), and during the opioid-free (OF) observation week in 30 patients who completed the trial. Global QLi: sumscore of 13 items of quality of life index; Factor 1, 2, 3: subfactors of QLi, see methods. Error bars: 95% confidence intervals. Significance level: *P < 0.01; **P < 0.005 Journal of Pain and Symptom Management 1998 16, 220-229DOI: (10.1016/S0885-3924(98)00070-0)